Homocysteine and Lipid Levels in Hypertensive Coronary Heart Patients

Abstract

Aim: As in many countries, coronary heart disease (CHD) is the leading cause of death in our country. Modifiable risk factors for CHD include smoking, hypertension, diabetes, diet, obesity, sedentary life, and hyperlipidemias. The aim of this study was to determine the homocysteine, Lp (a), von Willebrand factor (VWF) levels in male CHD which do not contain any irreversible risk factors.

Material and method: In our study, male subjects with similar body mass indexes around 50- 55 years of age, gender, familial predisposition, and non-modifiable risk factors were included in the study. Patients with CHD did not have any risk factors (10 patients, Group I), CHD and only hypertension (18 patients). Factor levels of homocysteine, Lp (a) and von Willebrand were
compared between Group II) and control group (52 healthy, Group III).

Result: Homocysteine levels, Group I: 16.5 ± 4.1 µmol / L, Group II: 20.1 ± 6.2 µmol / L, Group III: 11.8 ± 2.4 µmol / L, Lp (a) levels, Group I: 24.5 ± 6.1 mg / dl Group II: 36.6 ± 5.5 mg / dl, Group III: 20.8 ± 4.6 mg / dl. VWF levels were determined as Group I: 216.5 ± 12.8 mU / ml, Group II: 223.8 ± 9.2 mU / ml, and Group III: 86.9 ± 19.5 mU / ml. Homocysteine, Lp (a), VWF levels were significantly higher in both groups with CHD (p <0.05).

Conclusion: It is thought that homocysteine, Lp (a) and VWF should be among the routine tests such as other lipid parameters in the diagnosis of CHD.